Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Carlsmed (CARL) Research & Development (2024 - 2026)

Carlsmed filings provide 2 years of Research & Development readings, the most recent being $2.9 million for Q4 2025.

  • On a quarterly basis, Research & Development fell 67.93% to $2.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $20.4 million, a N/A change, with the full-year FY2025 number at $8.7 million, down 39.02% from a year prior.
  • Research & Development hit $2.9 million in Q4 2025 for Carlsmed, down from $4.4 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $9.0 million in Q4 2024 to a low of $1.9 million in Q2 2024.